Indaptus Therapeutics (NASDAQ:INDP) Trading Up 5.7% – What’s Next?

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s share price traded up 5.7% during trading on Thursday . The stock traded as high as $4.04 and last traded at $3.9850. 179,677 shares changed hands during trading, a decline of 72% from the average session volume of 630,641 shares. The stock had previously closed at $3.77.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on INDP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a research note on Saturday, June 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Indaptus Therapeutics Price Performance

The stock has a 50 day simple moving average of $1.88 and a 200-day simple moving average of $2.22. The firm has a market cap of $531.50 million, a PE ratio of -0.63 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last released its earnings results on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.